隶属于 university of georgia system board of regents
相关临床试验
59
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1913
进行中（未招募）
3
5.1%
已完成
35
59.3%
尚未招募
2
3.4%
招募中
12
20.3%
暂停
1
1.7%
终止
1
1.7%
Unknown
1
1.7%
撤回
4
6.8%
暂无批准数据
- GHP-88310, a broad-spectrum viral polymerase inhibitor, completely blocked airborne and direct-contact transmission of a measles-like virus in a ferret model. - Prophylactic administration before or after exposure prevented viral spread, while therapeutic use shortened the infectious period in already-infected animals. - The study, published in Nature Microbiology, modeled real-world transmission scenarios including household contact and classroom-style airborne exposure. - Researchers at Georgia State University are now preparing GHP-88310 for formal clinical testing amid resurgent measles outbreaks across North America.
- DZ-002, a novel fluorescent dye-drug conjugate developed by Georgia State University and Da Zen Theranostics, has advanced to Phase 2 clinical trials targeting pancreatic cancer patients. - The therapy utilizes MHI-148, a compound that selectively binds to cancer cells and delivers targeted radiation while minimizing damage to healthy tissues. - Phase 2 trials will evaluate safety, dosage parameters, and therapeutic efficacy in pancreatic cancer patients at HOAG Cancer Center, focusing on extending remission and improving quality of life. - The treatment represents 14 years of research and offers potential applications for other solid tumors and lymphoma beyond pancreatic cancer.
